Maria Alfaiate joins Lundbeck as executive VP, commercial, corporate strategy
Lundbeck is welcoming Maria Alfaiate to the newly established role of executive vice president, commercial and corporate strategy, on Aug. 1.
Alfaiate will be part of the executive management team, and will be responsible for strengthening corporate strategic functions and enhancing global marketing efforts. Her focus will be on optimizing Lundbeck’s ability to capitalize on both present and future opportunities.
Alfaiate brings significant experience from the life science and pharmaceutical sectors globally. Her expertise in developing strategic plans and executing programs to deliver solutions for patients across diverse markets will play a pivotal role in shaping Lundbeck’s future growth.
[Read more: Lupin obtains FDA OK for generic Northera]
“I am delighted to welcome Maria to Lundbeck. Her impressive track record in strategic commercial leadership is a great asset to our company. Her ability to design and execute innovative plans, coupled with her deep understanding of global markets, will undoubtedly strengthen our corporate strategic functions, and support the success of therapies as they become available to patients,” said Charl van Zyl, president and CEO of Lundbeck.
“Embarking on this new journey, I am fueled by the possibilities ahead and the opportunity to be impactful. I am joining a remarkable group of individuals devoted to helping patients suffering from neurological or psychiatric conditions. The vision of making a positive contribution to people and society resonates tremendously at a personal level,” Maria Alfaiate said.
Alfaiate joins Lundbeck from Bayer where she recently served as senior vice president and global head of new products commercialization and portfolio strategy. Prior to this, she has held positions at AstraZeneca and MSD/ Merck, in global teams but also at country level.
Alfaiate is of Portuguese nationality and holds a Master of Clinical Psychology from Universidade de Coimbra, Portugal.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars]